Baseline characteristics
| Variable . | Total (n = 562) . | No HTN at baseline (n = 215) . | HTN present at baseline (n = 347) . |
|---|---|---|---|
| Age, mean y (SD) | 63.8 (10.8) | 60.8 (10.5) | 65.6 (10.7) |
| Sex, n (%) | |||
| Male | 397 (70.6) | 149 (69.3) | 248 (71.5) |
| Female | 165 (29.4) | 66 (30.7) | 99 (28.5) |
| Race, n (%) | |||
| White | 521 (92.7) | 206 (95.8) | 315 (90.8) |
| African American | 30 (5.3) | 4 (1.9) | 26 (7.5) |
| Other* | 2 (0.4) | 0 (0.0) | 2 (0.6) |
| BMI, mean (SD) | 28.0 (5.5) | 26.2 (4.8) | 29.1 (5.7) |
| BMI, n (%) | |||
| <25 | 180 (32.0) | 96 (44.7) | 84 (24.2) |
| 25-29.9 | 228 (40.6) | 88 (40.9) | 140 (40.4) |
| ≥30 | 154 (27.4) | 31 (14.4) | 123 (35.5) |
| Other baseline traditional HTN risk factors | |||
| DM | 78 (13.9) | 15 (7.0) | 63 (18.2) |
| MI | 37 (6.6) | 9 (4.2) | 28 (8.1) |
| CAD | 65 (11.6) | 15 (7.0) | 50 (14.4) |
| CKD | 130 (23.1) | 40 (18.6) | 90 (25.9) |
| CHF | 15 (2.7) | 3 (1.4) | 12 (3.5) |
| AF | 25 (4.5) | 10 (4.7) | 15 (4.3) |
| Smoking status | |||
| Never | 306 (54.5) | 125 (58.1) | 181 (52.2) |
| Previous | 232 (41.3) | 82 (38.1) | 150 (43.2) |
| Current | 24 (4.3) | 8 (3.7) | 16 (4.6) |
| Primary malignancy, n (%) | |||
| CLL | 415 (73.8) | 168 (78.1) | 247 (71.2) |
| MCL | 58 (10.3) | 17 (7.9) | 41 (11.8) |
| WM | 10 (1.8) | 2 (0.9) | 8 (2.3) |
| Other† | 79 (14.1) | 28 (13.0) | 51 (14.7) |
| Rai stage, n (%)‡ | |||
| 0 | 2 (0.5) | 1 (0.6) | 1 (0.4) |
| 1 | 36 (8.7) | 17 (10.1) | 19 (7.7) |
| 2 | 80 (19.3) | 20 (11.9) | 60 (24.3) |
| 3 | 95 (22.9) | 41 (24.4) | 54 (21.9) |
| 4 | 201 (48.4) | 89 (53.0) | 112 (45.3) |
| Unknown | 1 (0.2) | 0 (0.0) | 1 (0.4) |
| CLL, risk stratification, n (%) | |||
| Del17p13 | 155 (37.4) | 73 (43.5) | 82 (33.2) |
| Del11q22 | 98 (23.6) | 35 (20.8) | 63 (25.5) |
| Trisomy 12 | 37 (8.9) | 12 (7.1) | 25 (10.1) |
| Del13q14 | 58 (14.0) | 26 (15.5) | 32 (13.0) |
| None of the above | 67 (16.1) | 22 (13.1) | 45 (18.2) |
| Baseline ECOG performance status, n (%) | |||
| 0 | 196 (34.9) | 78 (36.3) | 118 (34.0) |
| 1 | 321 (57.1) | 119 (55.3) | 202 (58.2) |
| 2 | 34 (6.0) | 11 (5.1) | 23 (6.6) |
| 3 | 2 (0.4) | 1 (0.5) | 1 (0.3) |
| 4 | 2 (0.4) | 1 (0.5) | 1 (0.3) |
| Unknown | 7 (1.2) | 5 (2.3) | 2 (0.6) |
| Treatment history, n (%) | |||
| Number of prior anticancer therapies, median (IQR) | 2 (0-5) | 2 (0-5) | 2 (0-5) |
| Prior anthracycline | 131 (23.3) | 51 (23.7) | 80 (23.1) |
| Concurrent anthracycline | 9 (1.6) | 3 (1.4) | 6 (1.7) |
| Prior chemotherapy | 469 (83.5) | 184 (85.6) | 285 (82.1) |
| Prior monoclonal antibody | 500 (89.0) | 199 (92.6) | 301 (86.7) |
| Prior targeted therapy | 105 (18.7) | 36 (16.7) | 69 (19.9) |
| Prior immunomodulatory | 76 (13.5) | 27 (12.6) | 49 (14.1) |
| CYP3A4 inhibitor | 33 (5.9) | 18 (8.4) | 15 (4.3) |
| Cyclosporine during ibrutinib use | 5 (0.9) | 1 (0.5) | 4 (1.2) |
| No prior anticancer therapies, n (%) | 35 (6.2) | 11 (5.1) | 24 (6.9) |
| Baseline mm Hg SBP, n (%) | |||
| <100 | 18 (3.2) | 17 (7.9) | 1 (0.3) |
| 100-119 | 136 (24.2) | 94 (43.7) | 42 (12.1) |
| 120-129 | 129 (23.0) | 85 (39.5) | 44 (12.7) |
| 130-139 | 142 (25.3) | 14 (6.5) | 128 (36.9) |
| 140-179 | 136 (24.2) | 5 (2.3) | 131 (37.8) |
| 180+ | 1 (0.2) | 0 (0.0) | 1 (0.3) |
| Baseline mm Hg DBP, n (%) | |||
| <70 | 256 (45.6) | 133 (61.9) | 123 (35.4) |
| 70-79 | 192 (34.2) | 64 (29.8) | 128 (36.9) |
| 80-89 | 101 (18.0) | 18 (8.4) | 83 (23.9) |
| 90-119 | 13 (2.3) | 0 (0.0) | 13 (3.7) |
| Baseline anti-HTN medications, n (%) | |||
| Beta-blocker | 131 (23.1) | 22 (10.2) | 109 (31.4) |
| ACE inhibitor/ARB | 118 (21.0) | 6 (2.8) | 112 (32.3) |
| Calcium channel blocker | 69 (12.3) | 3 (1.4) | 66 (19.0) |
| Diuretic§ | 89 (15.8) | 11 (5.1) | 78 (22.5) |
| Other¶ | 20 (3.6) | 2 (0.9) | 18 (5.2) |
| Variable . | Total (n = 562) . | No HTN at baseline (n = 215) . | HTN present at baseline (n = 347) . |
|---|---|---|---|
| Age, mean y (SD) | 63.8 (10.8) | 60.8 (10.5) | 65.6 (10.7) |
| Sex, n (%) | |||
| Male | 397 (70.6) | 149 (69.3) | 248 (71.5) |
| Female | 165 (29.4) | 66 (30.7) | 99 (28.5) |
| Race, n (%) | |||
| White | 521 (92.7) | 206 (95.8) | 315 (90.8) |
| African American | 30 (5.3) | 4 (1.9) | 26 (7.5) |
| Other* | 2 (0.4) | 0 (0.0) | 2 (0.6) |
| BMI, mean (SD) | 28.0 (5.5) | 26.2 (4.8) | 29.1 (5.7) |
| BMI, n (%) | |||
| <25 | 180 (32.0) | 96 (44.7) | 84 (24.2) |
| 25-29.9 | 228 (40.6) | 88 (40.9) | 140 (40.4) |
| ≥30 | 154 (27.4) | 31 (14.4) | 123 (35.5) |
| Other baseline traditional HTN risk factors | |||
| DM | 78 (13.9) | 15 (7.0) | 63 (18.2) |
| MI | 37 (6.6) | 9 (4.2) | 28 (8.1) |
| CAD | 65 (11.6) | 15 (7.0) | 50 (14.4) |
| CKD | 130 (23.1) | 40 (18.6) | 90 (25.9) |
| CHF | 15 (2.7) | 3 (1.4) | 12 (3.5) |
| AF | 25 (4.5) | 10 (4.7) | 15 (4.3) |
| Smoking status | |||
| Never | 306 (54.5) | 125 (58.1) | 181 (52.2) |
| Previous | 232 (41.3) | 82 (38.1) | 150 (43.2) |
| Current | 24 (4.3) | 8 (3.7) | 16 (4.6) |
| Primary malignancy, n (%) | |||
| CLL | 415 (73.8) | 168 (78.1) | 247 (71.2) |
| MCL | 58 (10.3) | 17 (7.9) | 41 (11.8) |
| WM | 10 (1.8) | 2 (0.9) | 8 (2.3) |
| Other† | 79 (14.1) | 28 (13.0) | 51 (14.7) |
| Rai stage, n (%)‡ | |||
| 0 | 2 (0.5) | 1 (0.6) | 1 (0.4) |
| 1 | 36 (8.7) | 17 (10.1) | 19 (7.7) |
| 2 | 80 (19.3) | 20 (11.9) | 60 (24.3) |
| 3 | 95 (22.9) | 41 (24.4) | 54 (21.9) |
| 4 | 201 (48.4) | 89 (53.0) | 112 (45.3) |
| Unknown | 1 (0.2) | 0 (0.0) | 1 (0.4) |
| CLL, risk stratification, n (%) | |||
| Del17p13 | 155 (37.4) | 73 (43.5) | 82 (33.2) |
| Del11q22 | 98 (23.6) | 35 (20.8) | 63 (25.5) |
| Trisomy 12 | 37 (8.9) | 12 (7.1) | 25 (10.1) |
| Del13q14 | 58 (14.0) | 26 (15.5) | 32 (13.0) |
| None of the above | 67 (16.1) | 22 (13.1) | 45 (18.2) |
| Baseline ECOG performance status, n (%) | |||
| 0 | 196 (34.9) | 78 (36.3) | 118 (34.0) |
| 1 | 321 (57.1) | 119 (55.3) | 202 (58.2) |
| 2 | 34 (6.0) | 11 (5.1) | 23 (6.6) |
| 3 | 2 (0.4) | 1 (0.5) | 1 (0.3) |
| 4 | 2 (0.4) | 1 (0.5) | 1 (0.3) |
| Unknown | 7 (1.2) | 5 (2.3) | 2 (0.6) |
| Treatment history, n (%) | |||
| Number of prior anticancer therapies, median (IQR) | 2 (0-5) | 2 (0-5) | 2 (0-5) |
| Prior anthracycline | 131 (23.3) | 51 (23.7) | 80 (23.1) |
| Concurrent anthracycline | 9 (1.6) | 3 (1.4) | 6 (1.7) |
| Prior chemotherapy | 469 (83.5) | 184 (85.6) | 285 (82.1) |
| Prior monoclonal antibody | 500 (89.0) | 199 (92.6) | 301 (86.7) |
| Prior targeted therapy | 105 (18.7) | 36 (16.7) | 69 (19.9) |
| Prior immunomodulatory | 76 (13.5) | 27 (12.6) | 49 (14.1) |
| CYP3A4 inhibitor | 33 (5.9) | 18 (8.4) | 15 (4.3) |
| Cyclosporine during ibrutinib use | 5 (0.9) | 1 (0.5) | 4 (1.2) |
| No prior anticancer therapies, n (%) | 35 (6.2) | 11 (5.1) | 24 (6.9) |
| Baseline mm Hg SBP, n (%) | |||
| <100 | 18 (3.2) | 17 (7.9) | 1 (0.3) |
| 100-119 | 136 (24.2) | 94 (43.7) | 42 (12.1) |
| 120-129 | 129 (23.0) | 85 (39.5) | 44 (12.7) |
| 130-139 | 142 (25.3) | 14 (6.5) | 128 (36.9) |
| 140-179 | 136 (24.2) | 5 (2.3) | 131 (37.8) |
| 180+ | 1 (0.2) | 0 (0.0) | 1 (0.3) |
| Baseline mm Hg DBP, n (%) | |||
| <70 | 256 (45.6) | 133 (61.9) | 123 (35.4) |
| 70-79 | 192 (34.2) | 64 (29.8) | 128 (36.9) |
| 80-89 | 101 (18.0) | 18 (8.4) | 83 (23.9) |
| 90-119 | 13 (2.3) | 0 (0.0) | 13 (3.7) |
| Baseline anti-HTN medications, n (%) | |||
| Beta-blocker | 131 (23.1) | 22 (10.2) | 109 (31.4) |
| ACE inhibitor/ARB | 118 (21.0) | 6 (2.8) | 112 (32.3) |
| Calcium channel blocker | 69 (12.3) | 3 (1.4) | 66 (19.0) |
| Diuretic§ | 89 (15.8) | 11 (5.1) | 78 (22.5) |
| Other¶ | 20 (3.6) | 2 (0.9) | 18 (5.2) |
ACE, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CYP3A4, cytochrome P450, family 3, subfamily A; DBP, diastolic blood pressure; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; MCL, mantle cell lymphoma; WM, Waldenström’s macroglobulinemia.
Hispanic, Asian, multiracial, and unknown race.
CLL alone.
Diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, graft-versus-host disease, and marginal zone lymphoma.
Includes loop, thiazide, and potassium-sparing diuretics.
Clonidine, hydralazine, nitrates, and α-1 antagonists.